

## Dear Region Director:

This report is designed to provide a comparative summary of treatment patterns and patient outcomes for End Stage Renal Disease (ESRD) patients in this region, as compared to all patients in the United States. The statistics reported here include dialysis patients treated during 2021-2024 in the chronic dialysis facilities in this region and are based primarily on data from the ESRD Quality Reporting System (EQRS), Medicare claims, and data collected for CMS. Selected statistics from this profile are summarized below and region-to-region comparisons of key statistics are provided in the *Charts and Tables of Key Statistics by Region*.

Selected highlights for this Region are provided on the first few pages. For a complete description of the methods and data reported here please see the *Guide to the Region Profiles for FY 2026*. The Guide is available on the Dialysis Data website at [www.DialysisData.org](http://www.DialysisData.org). We hope this profile is of interest to you and is helpful in your survey efforts. We welcome your feedback on ways to improve future profiles.

## What's New This Year

As part of a continuing effort to improve the quality and relevance of this report for your region, the following change has been incorporated into the Region Profile for FY 2026: the Prevalent Standardized Waitlist Ratio (PSWR) was added to Table 5. This measure is similar to the Standardized Waitlist Ratio in the First Year (FySWR), but includes all eligible patients and includes time to all waitlists as opposed to just the first event. The PSWR improves reporting of access to transplantation for prevalent patients compared to the age-adjusted percentage of patient-months waitlisted reported in row 5m, given the focus on time to waitlisting (as opposed to percentage waitlisted in a year), and also includes more robust risk adjustments (similar to the FySWR with the inclusion of patient vintage).

SAMPLE

## **Region Highlights**

**Patient Characteristics:** On December 31<sup>st</sup>, 2024, 13.7% of patients in this region were treated in a nursing home during the year, compared to 13.3% nationally. See **Table 1** for detailed summaries of all patients treated during 2021-2024 in this region.

Form CMS-2728 collected data from 12,169 incident patients in this region in 2024. **Table 2** describes certain important characteristics of these patients at the time of their first outpatient dialysis session, including patients' demographics, medical coverage, primary cause of ESRD, modality, pre-treatment nephrological care, transplant options, and vascular access type. In 2024, the average age of patients in this region at incidence was 63 years, compared to the national average of 63 years. Among the incident patients in this region in 2024, 92.8% were informed of their transplant options, compared to 93.5% nationally. Also in 2024, 15.2% of incident patients in this region were not under the care of a nephrologist prior to ESRD therapy, compared to 15.7% nationally.

**Mortality:** There were 8,433 deaths among the patients treated in this region during 2024, while 8,495 would be expected based on their age, race, ethnicity, sex, diabetes status, duration of ESRD, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.97, which is 3% lower than expected. Of the deaths in this region in 2024, 27% were preceded by withdrawal from dialysis, compared to the national average of 23%. See **Table 3** of this profile for more detailed mortality statistics during 2021-2024 in this region.

**First Year Mortality:** There were 1,967 deaths among the incident patients treated in this region during 2023, while 1,964 would be expected based on their age, race, ethnicity, sex, diabetes status, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The First Year Standardized Mortality Ratio (SMR) of observed to expected deaths is 0.98, which is 2% lower than expected. Of the deaths among incident patients in this region in 2023, 27% were preceded by withdrawal from dialysis, compared to the national average of 24%. See **Table 3** of this profile for more detailed first year mortality statistics during 2021-2023 in this region.

**Hospitalization:** The Standardized Hospitalization Ratio (SHR) of observed to expected hospital admissions for patients in this region during 2024 is 0.95, indicating that these patients had 5% fewer admissions than expected based on characteristics of patients treated in this region. The Standardized Readmission Ratio (SRR) of observed to expected hospital readmissions in this region during 2024 is 1.00, indicating that these patients had 0% more readmissions than expected. See **Table 4** of this profile for additional hospitalization statistics during 2021-2024 in this region.

**Transplantation:** 1,885 patients under age 75 in this region during 2024 received their first transplant, while 1,869 would be expected based on the age of these patients. The Standardized Transplantation Ratio (STR) of observed to expected number of patients transplanted for this region is 1.13, which is 13% higher than expected. See **Table 5** of this profile for additional transplantation statistics during 2021-2024 in this region.

**Kidney Transplant Waitlist for Prevalent Patients:** The 2024 age-adjusted percent waitlisted in this region is 17.1%, which is 0.9% higher than the national adjusted percentage. See **Table 5** of this profile for additional transplant waitlist statistics during 2021-2024 in this region.

**Kidney Transplant Waitlist for Incident Patients:** The 2023 first-year Standardized Waitlist Ratio (FySWR) in this region is 1.03, which is 3% more patients waitlisted or living donor transplants than expected in this region. See **Table 5** of this profile for additional transplant waitlist statistics during 2021-2023 in this region.

**Influenza Vaccination:** On December 31, 2024, 79% of all patients treated in this region were vaccinated against influenza between August 1 and December 31, 2024, compared to 78% nationally. This difference is statistically significant ( $p < 0.05$ ) and is unlikely to be due to random chance. See **Table 6** of this profile for more information about vaccinated patients during 2021-2024 in this region.

**Anemia Management:** In 2024, 23.0% of eligible hemodialysis patient-months in this region had a hemoglobin value below 10 g/dL, compared to 23.3% nationally. In 2024, 22.1% of eligible peritoneal dialysis patient-months had a hemoglobin value below 10 g/dL, compared to 22.6% nationally. See **Table 7** of this profile for additional anemia management statistics in this region during 2021-2024.

**Dialysis Adequacy:** Of the eligible hemodialysis patient-months in this region in 2024, 97% had a Kt/V  $\geq 1.2$ , compared to 97% nationally. Of the eligible peritoneal dialysis patient-months in this region in 2024, 92% had a Kt/V  $\geq 1.7$ , compared to 92% nationally. See **Table 8** of this profile for more information on dialysis during 2021-2024 in this region.

**Mineral Metabolism:** In 2024, 17% of eligible patient-months in this region had a serum phosphorus value  $>7.0$  mg/dL, compared to 17% nationally. Also in 2024, 1.2% of eligible patient-months in this region had a calcium uncorrected value  $>10.2$  mg/dL, compared to 1.1% nationally. See **Table 9** of this profile for more mineral metabolism summaries in this region during 2021-2024.

**Vascular Access:** In 2024, 13% of the incident hemodialysis patients in this region had an arteriovenous (AV) fistula in use, compared to 12% in the nation. This region's 2024 Standardized Fistula Rate (SFR) for prevalent patients is 60%, which is 2% higher than the national SFR. Of the prevalent patients receiving hemodialysis treatment in this region, the long-term catheter rate was 18%, compared to 18% nationally. See **Table 10** of this profile for additional information about vascular access in this region during 2021-2024.

SAMPLE

# Region Profile for FY 2026 for Dialysis Patients and Facilities

## REGION SAMPLE

The tables below provide updates of COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2), 2021-2024. National averages for 2024 are reported for comparison.

**TABLE C1. COVID among Medicare Dialysis Patients, 2021-2024<sup>\*1</sup>**

Outcome Description		This Region				United States
		2021	2022	2023	2024	2024
1	Medicare dialysis patients (n)	53,490	51,420	50,793	50,789	n/a
2	Patients ever infected with COVID (n)	10,101	14,162	13,146	11,581	n/a
	Patients ever infected with COVID (% of 1)	18.2	27.5	26.0	23.0	22.8
3	Patients initially infected with COVID (n)	5,552	6,991	2,600	1,729	n/a
	Patients initially infected with COVID (% of 1)	9.9	13.8	5.4	3.5	3.4
<b>Deaths among Medicare patients</b>						
4	Deaths (n)	8,670	8,059	7,477	7,459	n/a
5	Deaths among patients ever infected with COVID (n)	2,470	2,870	2,517	2,287	n/a
	Deaths among patients ever infected with COVID (% of 4)	26.5	35.1	33.6	30.8	30.6
<b>Hospitalizations<sup>*2</sup> among Medicare patients</b>						
6	Hospitalizations (n)	30,706	29,827	29,561	29,205	n/a
7	Hospitalizations among patients ever infected with COVID (n)	7,539	10,138	9,012	7,711	n/a
	Hospitalizations among patients ever infected with COVID (% of 6)	23.4	33.8	30.6	26.7	26.4

**TABLE C2. COVID among Medicare Dialysis Patients Treated in Nursing Home (NH) Facilities, 2021-2024<sup>\*1</sup>**

Outcome Description		This Region				United States
		2021	2022	2023	2024	2024
1	Medicare NH dialysis patients (n)	9,272	9,037	9,169	9,417	n/a
2	Patients ever infected with COVID (n)	3,008	3,723	3,366	2,981	n/a
	Patients ever infected with COVID (% of 1)	30.8	40.8	36.9	31.9	31.7
3	Patients initially infected with COVID (n)	1,479	1,903	830	598	n/a
	Patients initially infected with COVID (% of 1)	14.8	21.4	9.6	6.6	6.4
<b>Deaths among Medicare NH patients</b>						
4	Deaths (n)	2,786	2,683	2,640	2,696	n/a
5	Deaths among patients ever infected with COVID (n)	981	1,173	1,057	973	n/a
	Deaths among patients ever infected with COVID (% of 4)	33.0	43.2	40.3	36.5	36.1
<b>Hospitalizations<sup>*2</sup> among Medicare NH patients</b>						
6	Hospitalizations (n)	7,843	7,668	7,785	7,838	n/a
7	Hospitalizations among patients ever infected with COVID (n)	2,551	3,232	2,912	2,512	n/a
	Hospitalizations among patients ever infected with COVID (% of 6)	30.7	41.9	37.7	32.3	32.0

[\*1] Includes patients with Medicare as primary insurer or with a Medicare Advantage plan. Table C2 includes patients who were treated in a nursing home at least one day during the year. See *Guide, Section XVII*.

[\*2] Hospitalization is defined as having at least one day in a hospital from Medicare inpatient claims during the reporting period.

Region Profile for FY 2026 for Dialysis Patients and Facilities  
REGION SAMPLE

**TABLE 1: Summaries for All Dialysis Patients Treated as of December 31<sup>st</sup> of each Year, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
1a	Patients treated on 12/31 of year (n)	48,292	47,721	47,861	47,695	476,949
1b	Average age (years)	62.5	62.5	62.7	62.8	62.6
1c	Age (% of 1a; sums to 100%)					
	< 18	0.2	0.3	0.3	0.3	0.2
	18-64	51.1	50.7	50.2	49.8	50.6
	65+	48.7	49.0	49.5	49.9	49.2
1d	Female (% of 1a)	41.8	41.6	41.4	41.4	41.8
1e	Race (% of 1a; sums to 100%)					
	African American	28.8	29.0	28.9	28.7	34.2
	Asian/Pacific Islander	6.5	6.6	6.7	6.8	7.1
	Native American	1.9	1.9	2.0	1.9	1.3
	White	62.4	61.9	61.4	60.8	55.7
	Other/Unknown/Missing	0.4	0.7	1.0	1.9	1.8
1f	Ethnicity (% of 1a; sums to 100%)					
	Hispanic	20.0	20.6	21.1	21.8	24.1
	Non-Hispanic	80.0	79.4	78.9	78.1	75.9
	Unknown	0.0	0.0	0.0	0.0	0.0
1g	Cause of ESRD (% of 1a; sums to 100%)					
	Diabetes	46.1	45.5	45.1	44.6	44.4
	Hypertension	27.1	27.4	27.7	27.9	31.1
	Glomerulonephritis	10.7	10.4	10.0	9.7	8.5
	Other/Unknown	15.8	16.5	17.0	17.5	15.7
	Missing	0.2	0.2	0.2	0.3	0.3
1h	Average duration of ESRD (years)	4.9	4.9	4.9	4.9	5.0
1i	Years since start of ESRD (% of 1a; sums to 100%)					
	<1	16.9	16.5	16.6	16.8	16.3
	1-2	17.1	18.1	17.7	17.6	17.3
	2-3	14.0	13.6	14.4	14.0	13.8
	3-6	25.8	25.8	25.6	26.0	26.2
	6+	26.2	25.9	25.7	25.6	26.3
1j	Nursing facility patients <sup>*2</sup> (% of 1a)	13.1	13.1	13.4	13.7	13.3
1k	Modality (% of 1a; sums to 100%)					
	In-center hemodialysis	83.9	83.2	82.8	82.5	83.3
	Home hemodialysis	2.9	3.2	3.6	4.0	3.8
	Continuous ambulatory peritoneal dialysis	1.4	1.4	1.6	1.7	1.5
	Continuous cycling peritoneal dialysis	11.4	11.8	11.8	11.5	11.0
	Other modality	0.4	0.4	0.3	0.3	0.3

n/a = not applicable.

[\*1] See *Guide, Section IV* for detailed information regarding the summaries included in Table 1.

[\*2] Includes patients who were treated at a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.

Region Profile for FY 2026 for Dialysis Patients and Facilities  
REGION SAMPLE

**TABLE 2: Characteristics of New Dialysis Patients, 2021-2024 (Form CMS-2728) <sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	
<b>Patient Characteristics</b>						<b>2024</b>
2a	Total number of patients with forms (n)	12,703	12,232	12,217	12,169	121,685
2b	Age (average years [0-95]) <sup>*2</sup>	63.0	62.8	63.0	63.0	63.0
2c	Female (% of 2a)	41.2	40.9	40.6	40.8	41.5
2d	Race (% of 2a; sums to 100%)					
	African American	23.0	23.5	22.9	22.6	27.8
	Asian/Pacific Islander	6.1	6.2	6.4	6.3	6.4
	Native American	1.7	1.7	1.9	1.7	1.2
	White	68.5	67.1	66.5	64.5	59.9
	Other/Unknown/Missing	0.7	1.5	2.3	4.9	4.8
2e	Hispanic (% of 2a)	18.1	18.6	19.0	19.9	21.6
2f	Primary cause of ESRD (% of 2a; sums to 100%)					
	Diabetes	46.8	45.3	45.1	43.9	43.4
	Hypertension	26.7	27.5	27.8	28.2	31.7
	Glomerulonephritis	7.0	7.2	6.9	6.7	5.7
	Other/Missing	19.5	20.0	20.1	21.2	19.2
2g	Medical Coverage (% of 2a; sums to 100%)					
	Employer group only	12.1	12.0	11.3	11.9	11.5
	Medicare only	42.4	43.4	43.3	39.6	40.6
	Medicaid only	15.7	15.7	16.1	16.2	15.3
	Medicare and Medicaid only	7.4	7.4	8.1	9.2	9.1
	Medicare and Other	8.7	9.0	9.3	10.6	9.6
	Other/Unknown	9.8	9.2	8.7	9.2	10.0
	None	3.9	3.3	3.2	3.4	4.0
2h	Body Mass Index					
	Male	28.2	27.9	27.8	27.7	27.6
	Female	29.2	28.8	28.6	28.4	28.4
2i	Employment (% of 2a)					
	Six months prior to ESRD treatment	35.7	38.7	37.7	38.1	36.8
	At first ESRD treatment	26.3	28.9	28.5	27.1	25.9
2j	Primary Modality (% of 2a; sums to 100%)					
	Hemodialysis	86.1	84.9	84.8	85.7	86.1
	CAPD/CCPD	13.9	15.1	15.2	14.3	13.9
	Other/Unknown/Missing	0.0	0.0	0.0	0.0	0.0
2k	Number of incident hemodialysis patients (n)	11,006	10,467	10,403	10,482	104,821
2l	Access used at first outpatient dialysis (% of 2k; sums to 100%)					
	Arteriovenous fistula	13.6	13.9	14.1	13.8	13.0
	Arteriovenous graft	2.4	2.7	2.7	2.8	3.0
	Catheter	83.8	83.1	82.9	83.0	83.5
	Other/Unknown/Missing	0.3	0.4	0.3	0.4	0.5
2m	Arteriovenous fistulae placed (% of 2k) <sup>*3</sup>	24.8	24.3	24.4	22.7	21.6
<b>Average Lab Values Prior to Dialysis <sup>*2</sup></b>						
2n	Hemoglobin (g/dL [5-20])	9.4	9.4	9.3	9.4	9.4
2o	Serum Albumin (g/dL [0.8-6.0])	3.4	3.4	3.4	3.5	3.5
2p	Serum Creatinine (mg/dL [0-33])	6.5	6.5	6.5	6.4	6.4
2q	GFR (ml/min [0-30])	9.9	9.8	9.9	10.0	10.0

(continued)

Region Profile for FY 2026 for Dialysis Patients and Facilities  
REGION SAMPLE

**TABLE 2 (continued): Characteristics of New Dialysis Patients, 2021-2024 (Form CMS-2728) <sup>\*1</sup>**

		This Region				United States
Measure Name		2021	2022	2023	2024	
Care Prior to ESRD Therapy						
2r	Received ESA prior to ESRD (% of 2a)	16.3	16.7	17.0	17.8	17.4
2s	Pre-ESRD nephrologist care (% of 2a; sums to 100%)					
	No	16.1	15.3	14.9	15.2	15.7
	Yes, <6 months	17.8	18.3	18.3	18.1	19.0
	Yes, 6-12 months	18.9	18.5	18.4	18.2	18.5
	Yes, >12 months	32.3	32.1	32.1	32.4	29.0
	Unknown	14.8	15.6	16.3	16.0	17.6
2t	Informed of transplant options (% of 2a)	90.0	91.6	92.1	92.8	93.5
2u	Patients not informed of transplant options (n)	1,130	898	856	762	7,621
2v	Reason not informed (% of 2u; may not sum to 100%)					
	Medically unfit	37.5	41.4	41.7	26.8	25.2
	Unsuitable due to age	0.0	0.0	0.0	0.1	0.1
	Psychologically unfit	0.0	0.0	0.0	0.0	0.0
	Patient declined information	7.9	11.9	7.9	3.3	3.2
	Patient has not been assessed	52.3	55.2	50.8	32.6	34.9
Comorbid Conditions						
2w	Pre-existing Comorbidity (% yes of 2a)					
	Congestive heart failure	26.8	25.7	25.9	27.8	27.7
	Atherosclerotic heart disease	12.2	11.2	11.5	20.2	19.3
	Other cardiac disorder	21.0	20.6	21.4	25.8	25.3
	CVD, CVA, TIA	8.3	8.1	8.1	9.7	9.8
	Peripheral vascular disease	8.4	7.5	7.8	10.0	9.6
	History of hypertension	86.9	86.5	86.9	88.1	89.1
	Diabetes	63.8	62.7	63.1	63.0	63.7
	Diabetes on insulin	42.4	41.1	40.9	41.2	41.0
	COPD	8.2	7.7	7.7	8.5	8.2
	Current smoker	6.8	6.8	7.0	8.0	7.7
	Cancer	7.1	6.9	6.9	8.8	8.3
	Alcohol dependence	2.0	2.0	2.0	2.6	2.3
	Drug dependence	1.8	2.0	2.0	2.8	2.5
	Inability to ambulate	5.9	5.5	5.5	9.1	9.3
	Inability to transfer	3.1	2.9	2.9	5.4	5.7
2x	Average number of comorbid conditions	3.0	3.0	3.0	3.3	3.3
	Standardized Modality Switch Ratio (SMoSR)	2021	2022	2023		2023
2y	Eligible patients (n)	11,778	11,227	10,980		109,911
2z	Patient-years at risk (n)	8,300	7,934	7,859		78,661
2aa	Number of modality switches (n)	1,055	1,010	991		9,915
2ab	Expected number of modality switches (n)	1,057	1,007	991		9,923
2ac	SMoSR (2aa/2ab) *A	1.08	1.11	1.08		1.00

n/a= not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section V* for detailed information regarding the summaries included in Table 2.

[\*2] For continuous variables, all summaries are computed based only on responses in range indicated in brackets for the variable.

[\*3] Includes all patients with AV fistulae, regardless of whether they recieved their hemodialysis treatments using their fistulae.

**TABLE 3: Mortality Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023)** <sup>\*1</sup>

Measure Name		This Region				United States
		2021	2022	2023	2024	
<b>All Patients: Standardized Mortality Ratio (SMR)</b>						<b>2024</b>
3a	Patients (n)	68,517	67,744	67,364	67,045	740,533
3b	Patient-years at risk (n)	48,782	47,925	47,856	47,913	491,294
3c	Deaths (n)	9,739	9,049	8,445	8,433	90,212
3d	Expected deaths (n)	10,372	9,430	8,575	8,495	87,435
3e	Withdrawal from dialysis prior to death (% of 3c)	24.7	26.3	27.0	27.1	22.7
3f	Deaths due to infections (% of 3c)	11.0	10.6	9.9	9.7	9.0
3g	Deaths due to cardiac causes (% of 3c)	43.0	44.1	44.8	44.3	45.1
3h	Deaths due to liver disease (% of 3c)	1.3	1.3	1.3	1.2	1.2
3i	Dialysis unrelated deaths (n; excluded from SMR)	53	59	54	53	541
3j	SMR (3c /3d ) <sup>*A, *2</sup>	0.91	0.95	0.96	0.97	1.03
3k	P-value <sup>*B</sup>	0.049	.	.	.	n/a
<b>New Patients: First-Year Standardized Mortality Ratio (FySMR)</b>						<b>2023</b>
3l	Patients (n)	12,703	12,232	12,217		122,171
3m	Patient-years at risk (n)	11,307	10,970	10,963		109,633
3n	Deaths (n)	2,254	2,005	1,967		19,668
3o	Expected deaths (n)	2,261	1,991	1,964		19,641
3p	Withdrawal from dialysis prior to death (% of 3n)	26.7	26.3	27.3		23.6
3q	Deaths due to infections (% of 3n)	9.9	9.4	9.5		8.8
3r	Deaths due to cardiac causes (% of 3n)	39.3	38.3	38.8		40.1
3s	Deaths due to liver disease (% of 3n)	2.6	2.4	2.3		2.0
3t	FySMR (3n /3o ) <sup>*A, *2</sup>	0.97	0.98	0.98		1.00
3u	P-value <sup>*B</sup>		.	.		n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section VI* for detailed information regarding the summaries included in Table 3.

[\*2] The SMRs (3j, 3t) are not shown if there are fewer than 3 expected deaths (3d,3o).



**TABLE 4: Hospitalization Summary for Medicare Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Medicare Dialysis Patients</b>						
4a	Medicare dialysis patients (n)	55,081	53,394	52,949	52,722	576,905
4b	Patient-years at risk (n)	37,776	36,817	36,777	36,590	372,253
<b>Standardized Hospitalization Ratio (SHR) for Days Hospitalized</b> <sup>*2</sup>						
4c	Total days hospitalized (n)	418,373	419,456	411,342	410,198	4,430,847
4d	Expected days hospitalized (n)	442,023	442,693	432,632	428,879	4,397,920
4e	SHR for Days (4c/4d) <sup>*A</sup>	0.91	0.92	0.92	0.92	1.00
4f	P-value for SHR (Days) <sup>*B</sup>	0.137	0.088	0.037	<0.01	n/a
<b>Standardized Hospitalization Ratio (SHR) for Hospital Admissions</b> <sup>*2, *3</sup>						
4g	Total admissions (n)	51,033	48,848	51,635	52,788	550,886
4h	Expected total admissions (n)	51,761	49,725	52,641	53,785	550,867
4i	SHR for Admissions (4g/4h) <sup>*A</sup>	0.96	0.95	0.95	0.95	1.00
4j	P-value for SHR (Admissions) <sup>*B</sup>	.	.	.	.	n/a
4k	Patients with septicemia (% of 4a)	12.3	12.4	12.4	12.5	12.3
4l	One day admissions (% of 4g)	8.8	8.4	8.4	8.1	7.8
4m	Average length of stay (days per admission)	7.7	8.0	7.7	7.5	8.0
4n	Admissions that originate in the ED (% of 4g)	82.0	83.1	83.0	83.2	84.6
<b>Standardized Emergency Department Encounter Ratio (SEDR)</b> <sup>*2</sup>						
4o	Emergency department (ED) events (n)	29,314	25,055	22,128	20,225	207,466
4p	Expected number of emergency department events (n)	29,523	25,358	22,520	20,522	208,897
4q	SEDR (4o/4p) <sup>*A</sup>	1.00	1.00	0.99	1.00	0.99
4r	P-value for SEDR <sup>*B</sup>	<0.01	0.151	0.037	<0.01	n/a
<b>Standardized Ratio of ED Encounters Occurring within 30 Days of Hospital Discharge (ED30)</b>						
4s	Index discharges (n)	24,479	20,979	19,341	18,022	180,215
4t	Total ED visits within 30 days of hospital discharge (n)	3,607	2,997	2,725	2,529	25,294
4u	Expected total ED visits within 30 days of hospital discharge (n)	3,336	2,749	2,477	2,267	22,673
4v	ED30 Ratio (4t/4u) <sup>*A</sup>	1.11	1.12	1.13	1.15	1.12
<b>Standardized Readmission Ratio (SRR)</b> <sup>*2</sup>						
4x	Index discharges (n)	46,989	45,741	46,993	47,406	474,064
4y	Total readmissions (n)	12,323	11,899	12,380	12,891	128,907
4z	Expected total readmissions (n)	11,925	11,414	11,895	12,505	125,047
4aa	SRR (4y/4z) <sup>*A</sup>	1.01	1.01	1.01	1.00	1.03

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section VII* for detailed information regarding the summaries included in Table 4. SEDR and ED30 statistics include only patients with Medicare as primary insurer and exclude patients with Medicare Advantage plans. All other summaries include patients with Medicare as primary insurer or with a Medicare Advantage plan.

[\*2] SHRs and SEDR are not shown if there are less than five patient-years at risk. SRR and ED30 ratios are not shown if fewer than 11 index discharges in the year.

[\*3] Rows 4g-4j exclude index COVID hospitalizations, while rows 4l-4n include all admissions. Row 4k includes diagnoses in any position on a hospital inpatient claim.

**TABLE 5: Transplantation and Waitlist Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023) under Age 75<sup>\*1</sup>**

		This Region				United States
Measure Name		2021	2022	2023	2024	
<b>Transplantation: All Transplants</b>						<b>2024</b>
5a	Eligible patients (n)	54,817	53,862	53,134	52,453	580,300
5b	Transplants (n)	1,968	2,001	2,094	2,098	21,194
<b>Transplantation: First Transplants</b>						
5c	Eligible patients (n)	51,271	50,381	49,714	49,116	540,737
5d	Patient-years at risk (n)	36,629	35,742	35,407	35,178	360,771
5e	Actual first transplants (n)	1,756	1,804	1,869	1,885	19,023
5f	Expected first transplants (n)	1,715	1,768	1,842	1,869	19,181
5g	Standardized Transplantation Ratio (STR; 5e/5f)	1.12	1.13	1.11	1.13	0.99
5h	P-value <sup>*B</sup>	0.025	0.047	0.060	0.020	n/a
<b>Dialysis Patients on the Waitlist</b>						
5i	Eligible patients (n)	53,990	52,821	51,836	51,000	510,003
5j	Patient-months at risk (n) <sup>*3</sup>	459,509	447,347	442,666	437,013	4,370,133
5k	Patient-months on the waitlist (% of 5j) <sup>*3</sup>	17.9	17.8	17.3	17.1	16.5
5l	Patient-months on the waitlist by subgroup (%) <sup>*C, *2</sup>					
	Age < 40	27.5	27.1	26.6	27.0	25.8
	Age 40-74	16.8	16.7	16.2	16.0	15.5
	Male	19.0	18.9	18.4	18.2	17.7
	Female	16.3	16.2	15.7	15.5	14.7
	African American	18.0	18.0	17.1	16.3	15.3
	Asian/Pacific Islander	25.4	25.4	24.3	24.0	24.0
	Native American	12.5	12.1	12.7	13.0	9.6
	White, Hispanic	16.9	16.3	15.9	15.9	16.7
	White, Non-Hispanic	17.6	17.6	17.4	17.5	16.5
	Other/Unknown race	17.0	17.5	17.6	16.8	15.7
	Diabetes	14.4	14.6	14.5	14.5	14.1
	Non-diabetes	20.9	20.4	19.6	19.3	18.5
	Previous kidney transplant	30.7	30.2	29.0	28.7	28.2
	No previous kidney transplant	16.9	16.8	16.4	16.2	15.7
	<2 years since start of ESRD	14.6	15.0	15.0	15.1	13.6
	2-4 years since start of ESRD	22.3	22.2	21.7	21.5	21.1
	5+ years since start of ESRD	17.4	16.6	15.6	15.2	15.5
5m	Age-adjusted percentage of patient-months waitlisted	17.8	17.6	17.2	17.1	16.2
5n	Patient-months on the waitlist in active status (% of 5j) <sup>*C</sup>	10.6	10.1	9.7	9.6	9.8
5o	Age-adjusted % of patient-months waitlisted in active status	10.5	9.9	9.7	9.6	9.6
<b>All Patients: Prevalent Standardized Waitlist Ratio (PSWR)</b>						
5p	Eligible patients (n)	43,901	41,128	39,146	37,642	415,011
5q	Patient-years at risk (n)	32,091	29,407	28,114	27,144	279,114
5r	Waitlist events (n) <sup>*3</sup>	2,126	2,155	2,217	2,333	23,329
5s	Expected waitlist events (n) <sup>*3</sup>	2,101	2,138	2,188	2,314	23,138
5t	PSWR (5r/5s) <sup>*A, *3</sup>	1.12	1.07	1.07	1.08	1.01
5u	P-value for PSWR <sup>*B</sup>	0.053	0.048	0.021	0.056	n/a

(continued)

**TABLE 5 (continued): Transplantation and Waitlist Summary for All Dialysis Patients (2021-2024) & New Dialysis Patients (2021-2023) under Age 75<sup>\*1</sup>**

Measure Name		This Region			United States
		2021	2022	2023	
<b>New Dialysis Patients: First-Year Standardized Waitlist Ratio (FySWR)</b>					<b>2023</b>
5v	Eligible Patients (n)	8,521	8,132	7,996	79,960
5w	Patient-years at risk (n)	7,593	7,296	7,172	71,719
5x	First waitlist events (n) <sup>*3</sup>	731	728	743	7,432
5y	Expected first waitlist events (n) <sup>*3</sup>	689	724	791	7,914
5z	FySWR (5x/5y) <sup>*A, *3</sup>	1.24	1.13	1.03	0.93
5aa	P-value for FySWR <sup>*B</sup>	0.077	0.034	.	n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide Section VIII* for detailed information regarding the transplant and waitlist summaries included in Table 5. Eligible patient-months (5j) include patients assigned to the facility on the last day of each month.

[\*2] The waitlist percentage for each subgroup is calculated as a rate of waitlisted patient-months to patient-months at risk in each subgroup. A missing value indicates that there were no eligible patients in the subgroup.

[\*3] An event is defined as a waitlisting or living-donor transplant. FySWR and PSWR are not shown if a facility has less than 2 expected waitlisted events or less than 11 eligible patients.

Region Profile for FY 2026 for Dialysis Patients and Facilities  
REGION SAMPLE

**TABLE 6: Influenza Vaccination Summary All Dialysis Patients, Flu Seasons during August 2021-December 2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	
						<b>2024</b>
6a	Eligible patients on 12/31 (n)	51,176	50,582	50,629	50,509	505,089
6b	Patients excluded due to medical contraindication (n)	555	1,257	968	1,009	10,091
<b>Full Flu Season (Aug. 1-Mar. 31 of following year)</b>						<b>2023</b>
6c	Patients vaccinated (% of 6a)	83.5	82.6	80.6		79.9
6d	P-value <sup>*2</sup> (for 6c compared to U.S. value <sup>*3</sup> )	<0.01	0.043	0.039		n/a
6e	Reason for no vaccination (% of 6a)					
	Declined vaccination	8.2	7.2	8.2		8.5
	Other reason or vaccine data not available	7.5	10.1	11.2		11.5
<b>Half Flu Season (Aug. 1-Dec. 31)</b>						<b>2024</b>
6f	Patients vaccinated (% of 6a)	82.5	81.6	79.4	78.7	78.0
6g	P-value <sup>*2</sup> (for 6f compared to U.S. value <sup>*4</sup> )	0.045	0.032	<0.01	0.037	n/a
6h	Patients vaccinated by subgroup (%) <sup>*5</sup>					
	Medicare	83.4	82.6	80.5	79.8	79.1
	Medicare Advantage	84.5	83.8	81.7	80.9	80.2
	Medicare as primary insurer	82.8	81.7	79.4	78.6	77.7
	Non-Medicare	77.0	76.0	73.2	72.9	72.8
	Dual Medicare/Medicaid eligible	81.5	80.9	79.0	78.2	77.6
	Age < 18	72.8	65.2	62.7	63.6	62.9
	Age 18-39	72.5	72.0	69.3	68.3	67.2
	Age 40-64	80.5	79.6	76.5	75.5	75.0
	Age 65-74	84.7	83.8	81.9	80.9	80.5
	Age 75+	87.0	86.0	85.0	84.6	83.9
	Male	82.4	81.1	78.7	77.7	77.1
	Female	82.6	82.2	80.3	79.7	78.9
	African American	77.5	77.5	74.0	74.0	74.1
	Asian/Pacific Islander	86.6	85.8	84.6	85.1	84.5
	Native American	81.7	80.4	82.0	80.1	82.1
	White	84.2	83.0	81.0	79.8	79.4
	Other/unknown race	75.0	75.8	73.0	75.9	74.7
	Hispanic	85.1	84.7	83.1	82.2	82.0
	< 1 year since start of ESRD	75.3	72.6	72.0	71.4	70.2
	1-2 years since start of ESRD	83.1	81.8	78.5	77.7	76.7
	3+ years since start of ESRD	85.2	85.3	83.1	82.1	81.7

n/a = not applicable

[\*1] See *Guide, Section X* for detailed information regarding the summaries included in Table 6. All Dialysis Patients are those treated on December 31<sup>st</sup> of the reporting year.

[\*2] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the region and national percentage is plausibly due to random chance.

[\*3] Compared to the U.S. value for that year and time period (08/01-03/31): 83% (2021), 82% (2022), 80% (2023).

[\*4] Compared to the U.S. value for that year and time period (08/01-12/31): 81% (2021), 81% (2022), 79% (2023), 78% (2024).

[\*5] A missing value indicates that there were no eligible patients in the subgroup.

**TABLE 7: Anemia Management Summaries for Adult Dialysis Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Hemoglobin and ESA for Adult Hemodialysis (HD) Patients</b>						
7a	Eligible HD patients (n)	53,052	51,970	51,619	51,532	510,185
7b	Eligible HD patient-months (n) <sup>*C</sup>	494,598	483,853	482,607	481,206	4,812,059
7c	Average hemoglobin (g/dL) (average of 7b)	10.8	10.7	10.8	10.8	10.7
7d	Hemoglobin categories (% of 7b; sums to 100%)					
	<10 g/dL	22.8	23.2	22.9	23.0	23.3
	10-<11 g/dL	34.1	33.9	32.8	33.1	33.2
	11-12 g/dL	28.5	28.4	29.7	29.6	29.6
	>12 g/dL	12.8	12.3	13.1	13.0	12.6
	Missing/Out of range	1.9	2.1	1.5	1.2	1.3
7e	ESA prescribed (% of 7b)	75.7	75.9	76.6	77.0	77.6
<b>Hemoglobin and ESA for Adult Peritoneal Dialysis (PD) Patients</b>						
7f	Eligible PD patients (n)	8,329	8,347	8,440	8,356	82,768
7g	Eligible PD patient-months (n) <sup>*C</sup>	66,779	66,926	67,928	68,369	683,685
7h	Average hemoglobin (g/dL) (average of 7g)	11.0	10.9	11.0	11.0	11.0
7i	Hemoglobin categories (% of 7g; sums to 100%)					
	<10 g/dL	21.9	22.6	22.1	22.1	22.6
	10-<11 g/dL	28.0	27.8	27.2	27.6	28.0
	11-12 g/dL	26.5	26.2	26.8	27.0	26.7
	>12 g/dL	20.5	20.0	21.2	21.0	20.2
	Missing/Out of range	3.1	3.4	2.7	2.3	2.5
7j	ESA prescribed (% of 7g)	53.9	53.4	53.7	53.9	55.1
<b>Standardized Transfusion Ratio (STrR)</b>						
7k	Adult Medicare patients (n)	28,238	23,798	21,317	19,834	212,388
7l	Patient-years at risk (n)	16,549	13,936	12,269	11,066	112,000
7m	Total transfusions (n)	5,598	4,456	3,883	3,418	36,453
7n	Expected total transfusions (n)	5,790	4,667	4,065	3,593	36,486
7o	STrR(7m/7n) <sup>*A, *1</sup>	0.93	0.92	0.91	0.91	0.99
7p	P-value <sup>*B</sup>	0.106	0.084	<0.01	0.011	n/a

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XI* for detailed information regarding the summaries included in Table 7. Transfusion summaries include adult Medicare dialysis patients only and not shown if there are fewer than 10 patient-years at risk (7o).

**TABLE 8: Dialysis Adequacy Summaries for All Dialysis Patients, 2021-2024**<sup>\*1</sup>

		This Region				United States
Measure Name		2021	2022	2023	2024	2024
<b>Adult Hemodialysis (HD) Adequacy</b>						
8a	Eligible HD patients (n)	53,052	51,970	51,619	51,532	510,185
8b	Eligible HD patient-months (n) <sup>*C</sup>	494,598	483,853	482,607	481,206	4,812,059
8c	Average serum albumin (g/dL) (average of 8b)	3.9	3.9	3.9	3.9	3.9
8d	Serum albumin categories (% of 8b; sums to 100%)					
	< 3.0 g/dL	2.2	1.9	1.8	1.8	1.7
	3.0-<3.5 g/dL	8.9	8.2	8.1	8.1	7.9
	3.5-<4.0 g/dL	37.3	37.5	40.2	40.5	40.2
	>=4.0 g/dL	48.8	49.1	47.5	47.7	48.0
	Missing	2.8	3.3	2.3	1.9	2.1
8e	Ultrafiltration rate average (ml/kg/hr) (average of 8b)	7.6	7.6	7.6	7.5	7.6
8f	Ultrafiltration rate categories (% of 8b; sums to 100%)					
	<=13 (ml/kg/hr)	87.4	86.7	87.1	88.1	87.9
	>13 (ml/kg/hr)	7.6	7.7	7.6	7.2	7.5
	Out of Range (>=20 ml/kg/hr)	2.3	2.5	2.6	2.5	2.3
	Missing	2.7	3.1	2.7	2.1	2.3
8g	Eligible HD Kt/V patients (n) <sup>*2</sup>	50,398	49,374	48,927	48,623	481,560
8h	Eligible HD Kt/V patient-months (n) <sup>*C, *2</sup>	462,388	452,506	451,021	447,119	4,471,189
8i	Average Kt/V (average of 8h) <sup>*2</sup>	1.6	1.6	1.6	1.6	1.6
8j	Kt/V categories (% of 8h; sums to 100%) <sup>*2</sup>					
	<1.2	1.6	1.9	1.5	1.6	1.6
	1.2-<1.8	70.5	71.6	69.9	71.9	72.0
	>=1.8	26.3	24.7	27.2	25.3	25.1
	Missing/Out of range	1.5	1.8	1.4	1.2	1.3
<b>Adult Peritoneal Dialysis (PD) Adequacy</b>						
8k	Eligible PD patients (n)	8,329	8,347	8,440	8,356	82,768
8l	Eligible PD patient-months (n) <sup>*C</sup>	66,779	66,926	67,928	68,369	683,685
8m	Average Weekly Kt/V (average of 8l) <sup>*2</sup>	2.2	2.2	2.2	2.2	2.2
8n	Weekly Kt/V categories (% of 8l; sums to 100%) <sup>*2</sup>					
	<1.7	5.0	5.3	5.0	4.9	4.8
	1.7-<2.5	68.4	68.0	67.8	68.3	68.3
	>=2.5	23.7	23.6	24.4	23.9	24.0
	Missing/Out of range	2.9	3.1	2.8	2.8	2.9
8o	Average serum albumin (g/dL) (average of 8l)	3.7	3.7	3.7	3.7	3.7
8p	Serum Albumin Categories (% of 8l; sums to 100%)					
	< 3.0 g/dL	6.2	5.6	5.1	5.0	4.9
	3.0-<3.5 g/dL	21.3	20.4	20.3	20.5	20.5
	3.5-<4.0 g/dL	41.5	42.9	44.7	45.0	45.0
	>=4.0 g/dL	27.9	27.8	27.1	26.8	26.9
	Missing	3.1	3.4	2.8	2.6	2.7

(continued)

**TABLE 8 (continued): Dialysis Adequacy Summaries for All Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Pediatric Kt/V</b> <sup>*2</sup>						
8q	Eligible Pediatric HD patients (n)	72	77	78	84	833
8r	Eligible Pediatric HD patient-months (n) <sup>*C</sup>	477	526	532	567	5,667
8s	Average Kt/V (average of 8r)	1.7	1.8	1.7	1.7	1.7
8t	Kt/V categories (% of 8r; sums to 100%)					
	<1.2	2.5	2.9	2.6	2.0	2.2
	1.2-<1.8	56.9	52.4	59.5	56.8	54.9
	>= 1.8	32.6	35.3	29.6	29.6	27.7
	Missing/Out of Range	8.1	9.3	8.3	11.5	15.2
8u	Eligible Pediatric PD Patients (n)	97	93	92	87	867
8v	Eligible Pediatric PD patient-months (n) <sup>*C</sup>	714	708	697	626	6,262
8w	Average Weekly Kt/V (average of 8v)	2.4	2.4	2.4	2.4	2.4
8x	Weekly Kt/V categories (% of 8v; sums to 100%)					
	<1.7	11.6	12.2	12.2	12.6	13.1
	1.7-<2.5	49.0	47.0	48.4	47.6	48.7
	>=2.5	31.8	30.8	32.0	32.6	30.3
	Missing/Out of Range	7.7	10.0	7.4	7.2	7.9

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XII* for detailed information regarding the summaries included in Table 8.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. The most recent value over a 4-month period is selected for PD Kt/V.

**TABLE 9: Mineral Metabolism Summaries for All Adult Dialysis Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
9a	Eligible adult patients (n)	59,722	58,680	58,414	58,324	577,189
9b	Eligible adult patient-months (n) <sup>*C</sup>	562,812	552,207	551,893	550,887	5,508,873
9c	Average Phosphorus (mg/dL) <sup>*2</sup>	5.5	5.5	5.5	5.6	5.6
9d	Phosphorus categories (% of 9b; sums to 100%) <sup>*2</sup>					
	<3.5 mg/dL	6.8	7.4	7.3	7.0	7.1
	3.5-4.5 mg/dL	22.2	22.7	22.4	21.7	21.7
	4.6-5.5 mg/dL	29.2	28.4	27.5	27.1	27.1
	5.6-7.0 mg/dL	22.9	22.6	24.1	24.9	24.8
	>7.0 mg/dL	16.2	16.0	16.4	17.3	17.4
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	2.7	3.0	2.2	1.9	2.0
9e	Average Calcium Uncorrected (mg/dL)	8.9	8.9	8.8	8.9	8.9
9f	Calcium Uncorrected categories (% of 9b; sums to 100%)					
	<8.4 mg/dL	18.7	19.0	20.4	19.4	19.3
	8.4-10.2 mg/dL	77.7	77.2	76.5	77.7	77.8
	>10.2 mg/dL	1.2	1.2	1.0	1.2	1.1
	Out of Range (<0.01 mg/dL or >20 mg/dL)	0.0	0.0	0.0	0.0	0.0
	Missing	2.4	2.6	2.0	1.7	1.8
9g	Average uncorrected calcium > 10.2 mg/dL (%) <sup>*3</sup>	1.7	1.7	1.4	1.2	1.2

n/a = not applicable.

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XIII* for detailed information regarding the summaries included in Table 9.

[\*2] Eligible patients included in the phosphorous summaries differ slightly from what is reported in 9b since it includes patient-months within the first 90 days of ESRD.

[\*3] Hypercalcemia is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Eligible patients included in the hypercalcemia summary differs slightly from what is reported in 9b since patients must be 18 as of the first day of the 3-month period.



**TABLE 10: Vascular Access Information for all Adult Dialysis Patients and Access-Related Infection Summaries for all Medicare Patients, 2021-2024**<sup>\*1</sup>

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Vascular Access</b> <sup>*2</sup>						
10a	Prevalent adult hemodialysis (HD) patients (n)	55,905	54,686	54,060	53,931	533,945
10b	Prevalent adult hemodialysis patient months (n) <sup>*C</sup>	515,647	503,981	499,572	497,037	4,970,374
10c	Vascular access type in use (% of 10b; sums to 100%)					
	Arteriovenous fistula	62.3	61.1	60.3	59.5	58.6
	Arteriovenous graft	15.7	15.3	15.3	15.5	16.7
	Catheter	20.1	21.8	23.0	24.0	23.6
	Other/Missing	1.9	1.9	1.4	1.0	1.1
10d	Standardized Fistula Rate (SFR) <sup>*3</sup>	62.3	61.1	60.6	59.8	58.1
10e	Long-Term Catheter Rate <sup>*4</sup>	15.1	16.6	17.4	18.0	17.9
<b>Vascular Access at First Treatment</b>						
10f	Incident adult hemodialysis patients (n)	11,134	10,558	10,478	10,610	106,095
10g	Vascular access type in use (% of 10f; sums to 100%)					
	Arteriovenous fistula	13.5	13.5	13.5	13.1	12.3
	Arteriovenous graft	2.7	3.0	3.1	3.1	3.4
	Catheter	82.0	81.8	81.9	80.2	80.5
	Other/Missing	1.7	1.7	1.5	3.6	3.8
10h	Arteriovenous fistulae in placed (% of 10f) <sup>*5</sup>	14.2	14.2	14.2	13.5	12.8
<b>Infection: Peritoneal dialysis (PD)</b>						
10i	Eligible PD patients (n)	4,746	4,234	3,974	3,723	37,230
10j	Eligible PD patient-months (n) <sup>*C</sup>	32,882	29,460	27,447	25,763	257,634
10k	PD catheter infection rate per 100 PD patient-months	2.6	2.5	2.4	2.3	2.4
10l	P-value <sup>*6</sup> of 10k (compared to U.S. value <sup>*7</sup> )	0.118	0.139	0.179	0.094	n/a

n/a = not applicable

[\*A - \*C] See **Appendix: Table Footnotes** on page 22.

[\*1] See *Guide, Section XIV* for detailed information regarding the summaries included in Table 10.

[\*2] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded.

[\*3] Includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. SFR is calculated as an adjusted rate of AV fistula in use reported in 10c.

[\*4] Includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (10c) are also counted as catheter in use in the numerator.

[\*5] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[\*6] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random change.

[\*7] Compared to U.S. value for that year: 2.59 (2021), 2.47 (2022), 2.47 (2023), and 2.41 (2024).

**TABLE 11: Comorbidities Reported on Inpatient Medicare Claims for Medicare Dialysis Patients Treated as of December 31<sup>st</sup> of Each Year, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
11a	Medicare dialysis patients on 12/31(n)	38,243	36,992	37,046	36,948	376,446
11b	Comorbidity (% yes of 11a)					
	<b>Infections</b>					
	AIDS/HIV positive	0.7	0.7	0.7	0.7	0.8
	Intravascular/implanted device-related <sup>*2</sup>	4.6	4.6	4.7	4.5	4.7
	Hepatitis B	0.4	0.4	0.4	0.4	0.4
	Hepatitis other	1.7	1.6	1.5	1.3	1.4
	Metastatic	1.4	1.5	1.6	1.6	1.6
	Pneumonia	3.2	3.5	3.7	3.8	3.9
	Tuberculosis	0.2	0.3	0.3	0.3	0.3
	Other	17.6	18.2	18.6	18.6	19.1
	<b>Cardiovascular</b>					
	Cardiac arrest	0.9	0.9	0.9	0.8	0.9
	Cardiac dysrhythmia	18.8	19.1	19.8	20.0	19.9
	Cerebrovascular disease	6.9	7.1	7.4	7.5	8.0
	Congestive heart failure	29.5	30.7	31.8	32.1	32.4
	Ischemic heart disease	25.6	25.9	26.4	26.3	26.7
	Myocardial infarction	7.4	7.8	8.2	8.5	8.8
	Peripheral vascular disease <sup>*3</sup>	16.5	16.5	17.2	17.3	17.8
	<b>Other</b>					
	Alcohol dependence	1.5	1.5	1.6	1.6	1.5
	Anemia	3.0	3.3	3.3	3.4	3.4
	Cancer	3.4	3.6	3.7	3.8	3.8
	Chronic obstructive pulmonary disease	14.1	14.5	15.1	15.2	14.9
	Diabetes	35.4	36.0	36.8	36.4	37.1
	Drug dependence	1.4	1.4	1.5	1.4	1.3
	Gastrointestinal tract bleeding	2.9	3.0	3.0	3.2	3.3
	Hyperparathyroidism	19.6	20.7	21.9	22.3	22.2
11c	Average number of comorbid conditions	2.2	2.2	2.3	2.3	2.3

n/a = not applicable.

[\*1] See *Guide, Section XV* for detailed information regarding the summaries included in Table 11. Based on patients with Medicare as primary insurer on 12/31 each year.

[\*2] This category includes bloodstream and other infections related to intravascular access and other implanted devices, not limited to dialysis access.

[\*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

**TABLE 12: Selected Summaries for Nursing Home (NH) Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Patient Characteristics</b>						
12.1a	Patients treated on 12/31 (n)	6,096	6,051	6,222	6,335	63,436
12.1c	Age (% of 12.1a; sums to 100%)					
	18-64	33.6	32.5	32.1	31.7	32.2
	65+	66.4	67.5	67.9	68.3	67.8
12.1d	Female (% of 12.1a)	47.6	48.2	47.4	46.9	46.9
12.1e	Race (% of 12.1a; sums to 100%)					
	African American	29.9	30.4	30.7	30.7	37.0
	Asian/Pacific Islander	4.0	4.3	4.6	4.5	4.6
	Native American	1.8	1.7	1.7	1.7	1.2
	White	64.0	63.2	62.3	62.0	56.2
	Other/Unknown/Missing	0.3	0.4	0.6	1.0	1.0
12.1f	Ethnicity (% of 12.1a; sums to 100%)					
	Hispanic	13.5	13.9	14.1	14.5	15.2
	Non-Hispanic	86.4	86.1	85.9	85.5	84.7
	Unknown	0.0	0.0	0.0	0.1	0.1
12.1g	Cause of ESRD (% of 12.1a; sums to 100%)					
	Diabetes	56.4	54.9	54.0	53.3	51.9
	Hypertension	24.5	25.3	25.4	25.7	28.8
	Glomerulonephritis	5.2	4.9	5.1	4.8	4.3
	Other	13.6	14.5	15.2	15.9	14.6
	Unknown/Missing	0.3	0.3	0.2	0.4	0.4
12.1i	Years since start of ESRD (% of 12.1a; sums to 100%)					
	< 1	22.1	20.6	20.9	20.9	20.6
	1-2	14.6	16.2	15.2	15.3	15.4
	2-3	12.6	11.9	13.0	12.3	12.3
	3-6	25.7	25.7	25.1	25.7	25.5
	6+	24.9	25.5	25.8	25.9	26.2
12.1k	Modality (% of 12.1a; sums to 100%)					
	In-center hemodialysis	93.5	92.9	91.8	90.8	90.2
	Home hemodialysis	2.9	3.9	5.1	6.2	7.1
	Continuous ambulatory peritoneal dialysis	0.3	0.2	0.2	0.3	0.2
	Continuous cycling peritoneal dialysis	2.5	2.2	2.2	2.0	1.9
	Other modality	0.9	0.8	0.7	0.7	0.7

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Characteristics of New Dialysis Patients</b>						
12.2a	Total number of patients with forms (n)	2,521	2,354	2,397	2,397	23,971
12.2g	Medical coverage (% of 12.2a; sums to 100%)					
	Employer group only	3.0	2.5	2.3	2.6	2.4
	Medicare (alone or combined w/ other insurance)	79.6	82.4	82.9	82.6	82.4
	Medicaid only	10.6	9.6	10.0	9.8	9.8
	Other/Unknown/None	6.9	5.5	4.8	5.1	5.4
12.2k	Number of incident hemodialysis patients (n)	2,571	2,409	2,460	2,451	24,505
12.2l	Access used at first outpatient dialysis (% of 12.2k; sums to 100%)					
	Arteriovenous fistula	6.7	7.3	7.5	7.1	6.3
	Arteriovenous graft	1.7	2.1	2.1	2.3	2.5
	Catheter	89.3	87.9	87.5	87.9	88.5
	Other/Unknown/Missing	2.3	2.7	2.8	2.7	2.7
12.2m	Arteriovenous fistulae placed (% of 12.2k)	16.5	16.3	16.6	15.0	13.3
12.2s	Pre-ESRD nephrologist care (% of 12.2a; sums to 100%)					
	No	18.3	17.0	16.3	16.5	16.4
	Yes, < 6 months	19.9	20.6	21.3	21.1	22.0
	Yes, 6-12 months	16.8	15.8	16.4	15.9	15.8
	Yes, > 12 months	23.5	23.9	23.1	23.2	20.2
	Unknown	21.5	22.6	22.9	23.1	25.4
12.2t	Informed of transplant options (% of 12.2a)	84.1	86.5	86.6	68.2	68.8
<b>Mortality summary for all NH dialysis patients</b>						
12.3a	Patients (n)	11,169	11,170	11,382	11,609	142,652
12.3b	Patient-years at risk (n)	6,793.9	6,704.4	6,875.1	7,033.9	74,218.2
12.3c	Deaths (n)	2,915	2,774	2,749	2,791	31,319
12.3d	Expected deaths (n)	2,596.9	2,394.2	2,241.8	2,261.9	23,901.9
12.3c/12.3b	Death Rate (per 100 PYs at risk)	42.7	41.3	39.8	39.8	42.2
12.3j	Standardized Mortality Ratio (12.3c/12.3d)	1.09	1.13	1.19	1.21	1.31
12.3e	Withdrawal from dialysis prior to death (% of 12.3c)	30.9	32.0	32.4	32.0	26.3
<b>Hospitalization summary for NH Medicare dialysis patients</b>						
12.4a	Medicare dialysis patients (n)	10,046	9,940	10,147	10,398	126,824
12.4b	Patient-years at risk (n)	5,967.0	5,872.5	6,028.4	6,146.4	64,424.5
12.4g	Total admissions (n)	17,039	16,179	17,586	18,229	196,705
12.4h	Expected total admissions (n)	11,142.7	10,804.2	11,702.5	12,123.2	128,710.3
12.4g/12.4b	Hospitalization Rate (per 100 PYs at risk)	277.0	264.3	281.9	285.9	305.3
12.4i	Standardized Hospitalization Ratio (12.4g/12.4h)	1.48	1.44	1.45	1.45	1.53
	Diagnoses associated with hospitalization (% of 12.4a)					
	Septicemia	24.0	23.9	24.3	24.5	22.6
	Acute myocardial infarction	12.2	12.1	12.6	13.1	11.7
	Congestive heart failure	46.9	48.1	48.9	49.3	45.1
	Cardiac dysrhythmia	35.2	34.7	35.3	35.7	32.1
	Cardiac arrest	4.3	4.0	3.9	3.8	3.8

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients, 2021-2024<sup>\*1</sup>**

Measure Name		This Region				United States
		2021	2022	2023	2024	2024
<b>Comorbidities reported on Medicare claims</b>						
12.11a	Medicare dialysis patients on 12/31 (n)	5,431	5,313	5,487	5,626	59,411
12.11b	Comorbidity (% yes of 12.11a)					
<b>Infections</b>						
	AIDS/HIV positive	0.9	0.9	0.9	0.9	1.1
	Intravascular/implanted device-related	7.8	7.7	8.2	7.7	8.2
	Hepatitis B	0.7	0.7	0.7	0.7	0.8
	Hepatitis other	3.2	3.1	3.0	2.6	2.8
	Metastatic	3.8	4.2	4.4	4.6	4.6
	Pneumonia	8.7	9.3	9.9	9.8	10.6
	Tuberculosis	0.3	0.3	0.4	0.3	0.3
	Other	38.8	39.0	39.9	39.7	41.2
<b>Cardiovascular</b>						
	Cardiac arrest	2.4	2.2	2.4	2.1	2.5
	Cardiac dysrhythmia	39.1	38.9	39.9	39.3	39.7
	Cerebrovascular disease	17.8	18.2	18.8	18.4	20.1
	Congestive heart failure	54.2	55.8	57.0	56.6	57.6
	Ischemic heart disease	46.8	46.2	46.9	45.7	46.8
	Myocardial infarction	14.1	14.4	15.1	15.7	16.4
	Peripheral vascular disease	35.6	35.2	36.2	35.8	36.9
<b>Anemia</b>						
12.7b	Eligible adult HD patient-months (n) <sup>*C</sup>	73,080	71,912	73,797	75,171	751,709
12.7d	Hemoglobin (HD) < 10 g/dL (% of 12.7b)	30.3	29.9	29.7	30.1	30.9
12.7e	ESA prescribed (% of 12.7b)	79.7	79.7	80.5	81.1	81.5
12.7f	Eligible adult PD patients (n)	465	452	467	466	4,619
12.7g	Eligible adult PD patient-months (n) <sup>*C</sup>	2,704	2,571	2,699	2,737	27,372
12.7i	Hemoglobin (PD) < 10 g/dL (% of 7g)	27.4	27.9	28.5	27.4	28.0
12.7j	ESA prescribed (% of 7g)	55.7	56.2	56.6	55.0	55.6
<b>Dialysis Adequacy<sup>*2</sup></b>						
12.8b	Eligible adult HD Kt/V patient-months (n) <sup>*C</sup>	69,583	68,459	70,475	71,358	713,577
12.8j	Kt/V (HD) < 1.2 (% of 12.8b)	2.2	2.6	2.1	2.1	2.2
12.8k	Eligible adult PD Kt/V patients (n)	465	452	467	466	4,619
12.8l	Eligible adult PD Kt/V patient-months (n) <sup>*C</sup>	2,704	2,571	2,699	2,737	27,372
12.8n	Kt/V (PD) < 1.7 (% of 12.8l)	8.9	8.6	8.8	8.8	8.7
<b>Vascular Access<sup>*3</sup></b>						
12.10b	Prevalent adult hemodialysis patient months (n) <sup>*C</sup>	76,328	74,866	74,762	75,498	754,979
12.10c	Arteriovenous fistula in use (% of 12.10b)	51.7	50.4	50.6	50.0	48.3
12.10e	Long-Term Catheter Rate (LTCR)	20.7	22.2	22.4	22.6	23.0

n/a = not applicable; Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient's total body water.

[\*1] See *Guide, Section XVI* for detailed information regarding the summaries included in Table 12.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of *Guide* titled "Determination of Thrice Weekly Dialysis" for more information. PD Kt/V summaries select the most recent value collected within 4 months of the reporting month.

[\*3] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. Other or missing access types are counted as catheter in use in the numerator. LTCR includes patients using a catheter continuously for three months or longer.

## Appendix: Table Footnotes

This appendix provides information that applies to multiple tables.

[\*A] This value is the ratio of observed events to expected events.

[\*B] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value  $\geq 0.05$  indicates that the ratio is  $>1.05$  or  $<0.95$  plausibly due to random chance.

[\*C] A patient may be counted up to 12 times per year.

SAMPLE